Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
908 DevicesMASS +3.13%66 Cash-to-Debt is 23.93 as of Jun. 2026, which is 94% above its 10-year median of 12.35. GuruFocus rates MASS with a GF Score™ of 66/100 and a GF Value™ of $7.10 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 842 Medical Devices & Instruments companies, 908 Devices ranks better than 81.95% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. 908 Devices's cash to debt ratio for the quarter that ended in Jun. 2026 was 23.93.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, 908 Devicescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for 908 Devices's Cash-to-Debt or its related term are showing as below:
MASS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.39 Med: 12.35 Max: 33
Current: 23.62
During the past 8 years, 908 Devices's highest Cash to Debt Ratio was 33.00. The lowest was 0.39. And the median was 12.35.
MASS's Cash-to-Debt is ranked better than 81.95% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs MASS: 23.62
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
908 Devices Cash-to-Debt Related Terms
908 Devices Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for 908 Devices's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, 908 Devices's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
908 Devices Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, 908 Devices's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where 908 Devices's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
908 Devices (MASS) has a Cash-to-Debt of 23.93 as of Jun. 2026. This is 94% above median its historical median of 12.35. Over the past decade, 908 Devices' Cash-to-Debt has ranged from 0.39 to 33.00. According to the industry distribution chart, 908 Devices ranks #152 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 18.1%.
Is 908 Devices' Cash-to-Debt too high?
908 Devices' current Cash-to-Debt of 23.93 is 94% above median its 10-year median of 12.35. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 33.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. 908 Devices' value of 23.93 is 1363.6% above this industry median. Based on the distribution chart, 908 Devices ranks #152 out of 842 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, 908 Devices has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 908 Devices' Cash-to-Debt compare to SI and PACB?
According to the Medical Devices & Instruments industry distribution chart, 908 Devices ranks #152 out of 842 companies for Cash-to-Debt. This places 908 Devices in the top 18% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 1.64. 908 Devices' value of 23.93 is 1363.6% above this benchmark. Historically, 908 Devices' own Cash-to-Debt has ranged from 0.39 to 33.00 over the past decade. While the company's 10-year median is 12.35 vs. the industry median of 1.64, 908 Devices has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 908 Devices's current Cash-to-Debt of 23.93 is 1363.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 908 Devices's current Cash-to-Debt is 23.93, which is 94% above median its own 10-year median of 12.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 908 Devices stock overvalued right now?
Based on GuruFocus' analysis, 908 Devices (MASS) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.10, compared to a current price of $10.88 — trading 53.2% above its estimated fair value. The current Cash-to-Debt is 23.93, which is 94% above median its 10-year median of 12.35 and 1363.6% above the Medical Devices & Instruments industry median of 1.64. 908 Devices' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For 908 Devices (MASS), the current Cash-to-Debt is 23.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 908 Devices (MASS) Overvalued in 2026?
Based on GuruFocus' analysis, 908 Devices stock appears to be overvalued.
The current stock price of $10.88 is trading 53.2% above its estimated GF Value™ of $7.10.
GuruFocus considers 908 Devices to be Significantly Overvalued.
Key valuation signals for MASS:
Cash-to-Debt: 23.93 (94% above median its 10-year median of 12.35)
GF Value™: $7.10 vs. price of $10.88 (53.2% above fair value)
Industry Position: 1363.6% above the Medical Devices & Instruments median (#152 of 842)
No single metric tells the full story. See the MASS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.
66GF Score
Get the complete analysis for MASS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MASS has been successfully added to your 
